This work is licensed under a Creative Commons Attribution 4.0 International License.
Sequence 3 from Patent US 20060122119
General Information
DRACP ID DRACP01287
Peptide Name Sequence 3 from Patent US 20060122119
Sequence VPLDCVLYR
Sequence Length 9
PubChem CID Not available
Origin Homo sapiens
Type Native peptide
Classification
Active ACP
Activity Information
Hemolytic Activity Not available
Normal (non-cancerous) Cytotoxicity Not available
Target Not available
Affinity Not available
Mechanism Not available
Nature Antitumor
Structure Information
Helicity Not available
Linear/Cyclic Not available
Disulfide/Other Bond Not available
N-terminal Modification Not available
C-terminal Modification Not available
Other Modification None
Chiral L
Physicochemical Information
Formula C49H80N12O13S
Absent amino acids AEFGHIKMNQSTW
Common amino acids LV
Mass 122019
Pl 6.16
Basic residues 1
Acidic residues 1
Hydrophobic residues 4
Net charge 0
Boman Index -458
Hydrophobicity 84.44
Aliphatic Index 151.11
Half Life
Mammalian: 7.2 hour
Yeast: >20 hour
E.coli: >10 hour
Extinction Coefficient cystines 1490
Absorbance 280nm 186.25
Polar residues 2
Amino acid distribution
Literature Information
Literature 1
Pubmed ID Not available
Title Not available
Doi Not available
Year Not available
Patent
Patent ID US 2006/0122119 A1
Patent Title Peptides for use in antitumor immunotherapy.
Other Iinformation Granted Patent Family: 10s / 10ex; Family Jurisdictions: CA, AU, FR, WO, US, EP, JP; Legal Status: Discontinued; Application No: 50633405; Filed:May 25, 2005; Published: Jun 8, 2006; Earliest Priority: Mar 4, 2002
Other Published ID CA2477762A1 EP1481009A2 WO2003074565A2 WO2003074565A3
This work is licensed under a Creative Commons Attribution 4.0 International License.